The market size of the Global Advanced Therapy Medicinal Products CDMO market in the year 2021 is valued at 6.37 billion and is predicted to reach 16.15 billion by the year 2030 at an 11.25% CAGR during the forecast period.
Advanced therapy medicinal products are a class of human-use biological products that include gene therapy, cell therapy, and tissue-engineered products. The expanding clinical studies of ATMP and rising awareness and belief among researchers about the benefits of advanced treatment are associated with the market's expansion. The rising demand for sophisticated therapies is driving market expansion. The growth is attributable to the increasing occurrence of rare and life-threatening disorders, such as metabolic and ocular diseases, and increased investment in R&D of advanced therapeutic medical goods. Furthermore, ATMPs such as mesenchymal stem cells (MSCs) represent a novel treatment for the COVID-19 virus. Due to the complexity of the manufacturing process, the COVID-19 pandemic has dramatically affected the cell and gene therapy sector. Tissue engineering has significantly benefited from technological advances in recent years. This approach aids in the replacement or restoration of injured tissues and organ function.
Similarly, gene and cell therapy are attracting many patients to treat rare disorders, the prevalence of which is increasing globally. Numerous prominent players use market strategies such as technical alliances and collaborations, mergers and acquisitions, unique product debuts with approvals, R & D activities, strategic initiatives, training services, and regional expansion to build a stronghold in the market growth.
The Advanced Therapy Medicinal Products CDMO market is segmented on the product, phase, and indication. Based on product, the market is segmented into gene therapy, cell therapy, tissue-engineered and others (combined ATMPs, for example, biodegradable matric or scaffold). Based on phase, the Advanced Therapy Medicinal Products CDMO are segmented into phases I, II, III, and IV. Based on the indication, the Advanced Therapy Medicinal Products CDMO are segmented into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology and others.
Based on product, the gene therapy segment is accounted as a significant contributor to the Advanced Therapy Medicinal Products CDMO market.
Based on product, the market is segmented into gene therapy, cell therapy, tissue-engineered and others (combined ATMPs, for example, biodegradable matric or scaffold). The gene therapy segment is expected to account for the highest share of the market. The rapid expansion of the segment can be ascribed to therapeutic breakthroughs since the treatment can alter and improve genetics or modify the targeted treatment. Another aspect driving expansion is increased awareness, which leads to patients wanting this therapy even during the clinical stages. Gene therapy has seen rapid expansion in recent years because of its effectiveness in penetrating cells and beginning genetic materials.
The oncology segment witnessed growth at a rapid rate.
Based on the indication, the Advanced Therapy Medicinal Products CDMO are segmented into oncology, cardiology, central nervous system, musculoskeletal, infectious disease, dermatology, endocrine, metabolic, genetic, immunology & inflammation, ophthalmology, hematology, gastroenterology and others. The oncology segment dominated the market. The increasing incidence of cancer and chronic diseases due to the growing elderly population is contributed to the segment's growth. Oncology is a medical speciality that diagnoses and treats cancer. ATMPs were first used to find a breakthrough in cancer treatment, and as a result, this segment has seen the most expertise and effort over the years.
The North American Advanced Therapy Medicinal Products CDMO market holds a significant regional revenue share.
The North American Advanced Therapy Medicinal Products CDMO market is expected to register the highest market share in revenue shortly. The region is expected to account for the significant share of market revenue. North America's market relevance is achievable due to rising awareness of advanced therapy and expanding outsourcing operations. In addition, the United States has been a pioneer in R&D operations to provide new treatments to the healthcare business. As a result of these factors, the market is expected to grow at a rapid pace in the approaching years. In addition, Asia Pacific is projected to expand rapidly in the global Advanced Therapy Medicinal Products CDMO market because of developments in treatment technology and increased outsourcing activity in the region. The leading competitors in the advanced therapy medicinal products CDMO market are working hard to meet the region's need for advanced therapy therapeutic goods.
The key players in the Advanced Therapy Medicinal Products CDMO market have shifted their focus toward product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance their product portfolio and strengthen their global market footprint. Some major key players in the Advanced Therapy Medicinal Products CDMO market are Celonic; Bio Elpida; CGT Catapult; Rentschler Biopharma SE; AGC Biologics; Catalent; Lonza; WuXi Advanced Therapies; BlueReg; Minaris Regenerative Medicine; Patheon.